July 7, 2017 — Detection technology provider PerkinElmer Inc. has entered into a definitive agreement to acquire Euroimmun Medical Laboratory Diagnostics AG for $1.3 billion in cash. 

“I am delighted to entrust Euroimmun to PerkinElmer, a company I believe shares our important mission and will secure the continuity of our culture and tradition of innovation that we have developed over the last thirty years,” said Winfried Stöcker, founder and CEO of EuroImmun. 

based in Lübeck, Germany, with approximately 2400 employees, Euroimmun is a developer of autoimmune, infectious disease and allergy testing. The company has extensive expertise and capabilities across immunology, cell biology, histology, biochemistry and molecular biology. 

“With the acquisition of Euroimmun and its talented team of professionals, we are able to leverage our combined advanced detection, imaging and assay development capabilities, along with our strong collective market positions and synergistic commercial activities, to deliver better and more complete solutions to our customers around the world,” said Robert Friel, chairman and CEO of PerkinElmer. “We look forward to working with the Euroimmun team as we partner together to help improve global health through advanced diagnostics.” 

PerkinElmer’s global diagnostics portfolio will now include solutions focused on autoimmune, infectious disease and allergy testing, reproductive health, gene analyses and genomics offerings for oncology and other molecular tests through its range of instruments, reagents, assay platforms and software offerings. 

The transaction is expected to close in the fourth quarter of 2017.